Omeros Corporation (OMER) Given Average Rating of “Buy” by Brokerages
Omeros Corporation (NASDAQ:OMER) has earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the company. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $32.44.
Several research analysts recently issued reports on OMER shares. Wedbush reaffirmed an “outperform” rating and set a $56.00 target price on shares of Omeros Corporation in a research report on Friday, October 21st. FBR & Co reaffirmed an “outperform” rating and set a $38.00 target price on shares of Omeros Corporation in a research report on Tuesday, October 18th. WBB Securities reaffirmed a “buy” rating and set a $75.00 target price on shares of Omeros Corporation in a research report on Monday, October 17th. Maxim Group set a $19.00 price objective on Omeros Corporation and gave the company a “buy” rating in a report on Wednesday, November 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Friday, November 11th.
Omeros Corporation (NASDAQ:OMER) traded up 1.15% on Monday, hitting $13.22. The stock had a trading volume of 291,929 shares. The stock’s market cap is $567.34 million. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $16.80. The company’s 50 day moving average is $9.63 and its 200-day moving average is $10.86.
Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.06. The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $11.64 million. During the same period in the prior year, the company earned ($0.53) earnings per share. The company’s quarterly revenue was up 253.1% on a year-over-year basis. Analysts forecast that Omeros Corporation will post ($1.69) EPS for the current year.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the sale, the vice president now owns 179,597 shares in the company, valued at $1,959,403.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.60% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of OMER. State Board of Administration of Florida Retirement System increased its position in shares of Omeros Corporation by 1.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 30,737 shares of the biopharmaceutical company’s stock worth $323,000 after buying an additional 351 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Omeros Corporation during the second quarter worth about $762,000. Capital Fund Management S.A. acquired a new position in shares of Omeros Corporation during the third quarter worth about $245,000. Nationwide Fund Advisors increased its position in shares of Omeros Corporation by 0.9% in the second quarter. Nationwide Fund Advisors now owns 67,255 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 631 shares in the last quarter. Finally, Mesirow Financial Investment Management Equity Management acquired a new position in shares of Omeros Corporation during the second quarter worth about $244,000. Institutional investors own 52.08% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.